S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS

Detalles Bibliográficos
Autores principales: Daver, N. G., Vyas, P., Kambhampati, S., Al Malki, M. M., Larson, R., Asch, A., Mannis, G., Chai-Ho, W., Tanaka, T., Bradley, T., Jeyakumar, D., Wang, E., Xing, G., Chao, M., Ramsingh, G., Renard, C., Lal, I., Zeidner, J., Sallman, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642082/
http://dx.doi.org/10.1097/01.HS9.0000843420.50062.9b

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642082/
http://dx.doi.org/10.1097/01.HS9.0000843420.50062.9b

Ejemplares similares